(Total Views: 233)
Posted On: 04/26/2017 6:41:11 PM
Post# of 99217
$NEOT $2.08
Nasdaq GM
at resistance on 10 day
ultra low float
Website
Last ten trades
80% x 100% Strong Buy
10-K 3/23/17
Shares Outstanding 13.83M
Float 6.36M
% Held by Insiders 54.08%
% Held by Institutions 20.90%
Shares Short 207.87k
Short Ratio 2.37
Short % of Float 2.29%
Shares Short (prior month) 224.28k
Stock technical analysis
News
and filings
Neothetics, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutics for the aesthetic market. Its lead product candidate is LIPO-202, an injectable formulation of salmeterol xinafoate for the reduction of localized fat deposits under the chin, or submental fat, as well as for reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The company was formerly known as Lipothera, Inc. and changed its name to Neothetics, Inc. in August 2014. Neothetics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Nasdaq GM
at resistance on 10 day
ultra low float
Website
Last ten trades
80% x 100% Strong Buy
10-K 3/23/17
Shares Outstanding 13.83M
Float 6.36M
% Held by Insiders 54.08%
% Held by Institutions 20.90%
Shares Short 207.87k
Short Ratio 2.37
Short % of Float 2.29%
Shares Short (prior month) 224.28k
Stock technical analysis
News
and filings
Neothetics, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutics for the aesthetic market. Its lead product candidate is LIPO-202, an injectable formulation of salmeterol xinafoate for the reduction of localized fat deposits under the chin, or submental fat, as well as for reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The company was formerly known as Lipothera, Inc. and changed its name to Neothetics, Inc. in August 2014. Neothetics, Inc. was founded in 2007 and is headquartered in San Diego, California.
(0)
(0)
